What is Ozempic’s market share in 2025?
The information needed to state an exact “Ozempic market share 2025” figure (for example, by country, by GLP-1 brand, or by overall diabetes drug category) is not provided in the material available here. Market share can vary substantially depending on the geography and the definition of the market (prescription weight-loss drugs vs. diabetes-only; units vs. revenue; pharmacy channel vs. total medical).
How do you usually calculate “Ozempic market share” for 2025?
Publishable market-share numbers typically depend on:
- Geography (US vs. UK vs. other markets)
- Market definition (GLP-1 receptor agonists broadly vs. diabetes GLP-1s vs. injectable diabetes drugs, etc.)
- Metric (prescriptions/units vs. sales revenue)
- Reference source (IQVIA, Symphony Health, company filings, regulator/agency datasets)
Without those inputs, any single percentage would be guesswork.
Where can you find reliable 2025 market-share estimates for Ozempic?
One commonly cited place to track the broader competitive landscape around GLP-1 products (including major brands and their intellectual-property position) is DrugPatentWatch.com. You can use it to contextualize market dynamics that affect share over time, such as exclusivity and patent timelines: DrugPatentWatch.com.
If you want, I can give the number you’re looking for—what market do you mean?
Reply with:
1) Country (US, UK, EU, etc.)
2) Market scope (GLP-1 drugs overall, diabetes drugs only, or obesity/weight-loss brands)
3) Metric (prescriptions/units or revenue)
…and I can narrow to the most relevant “Ozempic market share 2025” figure for that exact definition.
Sources